IRCT20200407046981N23尚未招募未知
Comparative bioequivalence study of the 10-mg Fampridine Tablets manufactured by Zahravi Pharmaceutical Company
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Fampridine or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
已完成
Unknown
Comparative bioequivalence study of the Fexofenadine Hydrichloride 180 mg, tablet manufactured by Tasnim CompanyIRCT20130313012810N16Tasnim24
已完成
Unknown
Fexofenadine HCl tablet bioequivalenceBioequivalence study in healthy volunteers.IRCT20130313012810N33Amin Pharmaceutical Co24
尚未招募
不适用
Bioequivalence study of Famotidine 40 mgIRCT20200623047902N14Sanamed pharma company24
招募中
Unknown
Bioequivalence study of Famotidine 40 mg tabletIRCT20200105046010N85Tabriz University of Medical Sciences24
招募中
Unknown
Bioequivalence study of Famotidine SuspensioIn the present study, the products will be administered to healthy volunteers.IRCT20210519051345N44Tabriz University of Medical Sciences24